Navigation Links
Experimental Drug Fights Bone Marrow Cancers
Date:12/9/2008

There are currently no FDA-approved treatments for these malignancies

TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells.

The findings were to be presented Tuesday at the annual meeting of the American Society of Hematology, in San Francisco.

The researchers, from Oregon Health & Science University's Knight Cancer Institute, found that CYT387 was "very effective" against a specific type of cancer cell driven by an enzyme mutation called JAK2-V617F. The drug binds to the V617F mutation in the JAK2 enzyme.

"In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," researcher Dr. Thomas Bumm said in a university news release.

There are no U.S. Food and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis.

"Based on the efficacy we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009," principal investigator Dr. Michael Deininger, head of the hematological malignancies program, said in the news release.

The study was funded by Cytopia Research Pty Ltd. of Australia, which makes the drug.

More information

The Leukemia and Lymphoma Society has more about MPDs.



-- Robert Preidt



SOURCE: Oregon Health & Science University, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Experimental Vaginal Gel Doesnt Ward Off HIV
2. Experimental TB drug explodes bacteria from the inside out
3. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
4. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
5. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
6. Experimental Drug Fights Multiple Sclerosis Activity
7. Experimental Therapy Beats Back One Patients Melanoma
8. Experimental agent blocks prostate cancer in animal study
9. Experimental Drug Eases Symptoms of Mild Alzheimers
10. Experimental Blood Substitutes Unsafe, Study Finds
11. Honda to Showcase Experimental Walking Assist Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Bone Marrow Cancers
(Date:5/6/2016)... ... 2016 , ... A wide variety of national pet product manufacturers, companies and brands will gather ... Wednesday, May 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. ... established home, garden, outdoor and safety pet products in today’s marketplace. , Petrend ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate humidity ... is too cold, dry or hot, water on the eye surface can evaporate, creating ... the surrounding air. There’s only one problem, according to radio show and water advocate ...
(Date:5/6/2016)... ... , ... Canadian author Mark Black is a speaker, author, and life strategy coach ... world … with the help of his publisher Strategic Book Group and its subsidiary ... hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From this ...
(Date:5/6/2016)... ... ... Overseer at The House of Yahweh, has written a new article this week meant to ... stop cancer. Yisrayl says there are too many suffering and dying from the disease to ... pay close attention and take action. The Pastor says that the root cause of all ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... former president of Allergan, Inc. and current CEO of Chase ... of TPG Capital, to its Board of Directors. The appointments ... "Endo recently embarked on a search for new Board members ... Doug and Todd are experienced leaders, and we are extremely ...
(Date:5/5/2016)... Grand Cayman , May 5, 2016 Progra ... successful trial of Oxitec , s mosquito ... Aedes aegypti by 96 % ... (MRCU) announced a new plan to fight wild Aedes aegypti, the ... these diseases on the island of Grand Cayman .  MRCU, ...
(Date:5/5/2016)... May 5, 2016 Research and ... PET Imaging in the USA"  report to their offering.  ... information on the current Positron Emission Tomography (PET) scanner ... market. Along with the current known number ... USA , the report also contains a detailed ...
Breaking Medicine Technology: